Stock BIIB BIOGEN INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Biogen Inc.

Equities

BIIB

US09062X1037

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
224.9 USD +2.21% Intraday chart for Biogen Inc. +3.27% -13.07%
May. 31 Biogen: Brussels grants marketing authorization for Charcot disease CF
May. 31 Disaster averted Our Logo

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
NASDAQ: BIIB: Kessler Topaz Meltzer & Check, LLP Notifies Investors of a Securities Class Action Lawsuit Filed Against Biogen Inc.
BU
Biogen: Brussels grants marketing authorization for Charcot disease
CF
Disaster averted
Our Logo
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Biogen Inc. (BIIB) Investors
BU
European Commission grants marketing approval to Biogen's ALS drug
RE
Biogen Gets European Commission Approval for Qalsody
MT
Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
PR
Biogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS
GL
Biogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS
AQ
Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Biogen Inc. (BIIB) Investors
BU
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Biogen Inc. (BIIB) Investors
BU
BIIB Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
BU
BIIB Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
PR
Biogen Inc. Investor Notice: Robbins LLP Reminds Stockholders of the Class Action Against BIIB
BU
"LEQEMBI" Lecanemab) Approved for the Treatment of Alzheimer's Disease in South Korea
AQ
Biogen : “LEQEMBI®” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in South Korea
PU
BIIB Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
PR
Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Biogen Inc. (BIIB) Investors
BU
BIIB Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
BU
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Biogen Inc. with Losses to Contact the Firm
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BIIB Stock
  4. News Biogen Inc.